top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


The True Cost of a Poor Senior Hire in Life Sciences
A poor senior hire in Life Sciences can cost far more than recruitment fees and replacement expenses. Delayed milestones, lost productivity, weakened trust, and reduced willingness to speak up can all affect organizational performance. This article explores the financial and cultural impact—and how to reduce the risk before making a pivotal appointment.
sharonshieldsconsu
6 days ago4 min read


Integrating Teams After M&A or Strategic Partnerships
Value is driven by what happens bringing together individuals and teams In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months. This year has seen so many significant acquisition, across biotech and medtech, a few of the most
sharonshieldsconsu
Nov 126 min read


Succession Planning in Life Sciences: Your Most Overlooked Risk Management Tool
Succession planning in the life sciences industry is not a “nice to have” HR process—it’s a core element of risk management and business continuity. Unplanned leadership gaps can delay clinical trials, regulatory submissions, manufacturing, and product launches, directly impacting patients and revenue. In this article, we explore when, why and how life sciences organisations should approach leadership succession, the mission‑critical roles to prioritise, and practical steps.
sharonshieldsconsu
Nov 73 min read


Radiopharmaceuticals at Scale: Can Oncology Build the Infrastructure This Modality Requires?
Radiopharmaceuticals have moved from the periphery of oncology to the centre of pipeline and dealmaking conversations. What was once a niche, technically awkward modality is now a serious strategic bet for big pharma and specialist biotechs alike.
The science is compelling: take radiation we know can kill cancer cells, and deliver it with the precision of modern targeting ligands or antibodies. Early products in prostate cancer and neuroendocrine tumours have shown that, wit
sharonshieldsconsu
Oct 214 min read
bottom of page